Supercharged immune cells take on Hard-to-Treat cancers
NCT ID NCT07570563
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new treatment made from specially engineered immune cells (T cells) donated by healthy people. The cells are designed to better recognize and kill cancer cells while lasting longer in the body. The trial includes 24 adults with blood cancers or solid tumors that have not responded to standard treatments. The main goal is to check safety and how well the therapy works.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEMATOLOGIC MALIGNANCY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Biotherapeutic Department of Chinsese PLA Gereral Hospital
RECRUITINGBeijing, Beijing Municipality, 100853, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can specially trained immune cells flush out hidden HIV?
- Can a new drug shield nerves from Chemotherapy's side effects?
- Can a Tumor's DNA guide better cancer care for kids?
- Frailty check may steer safer cancer care for seniors
- Could gratitude exercises aid blood cancer recovery?
- Can a new PET tracer reveal a key cancer target?